RecruitingPhase 2Phase 3NCT02131753
Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Sponsor
University of Giessen
Enrollment
210 participants
Start Date
May 1, 2004
Study Type
INTERVENTIONAL
Conditions
Summary
The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment. They have to be untreated so far or may be pretreated with alpha-interferon.
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Inclusion Criteria17
- Patients with histologically verified hairy cell leukemia
- Presence of hairy cells in the bone marrow and peripheral blood detected by positive TRAP staining and / or co expression if cell surface antigens cluster of differentiation (CD) 19/CD25 or CD19/CD103 (b-ly7)
- No previous cytostatic treatment (splenectomy or interferon treatment are allowed)
- Need for treatment
- Age at least 18 years old
- General state of health according to WHO 0-2
- Current histology, not older than 6 months
- Written consent by patient
- Hairy cell leukemia variants (HCL-V): presence of lymphoid cells in bone marrow and / or peripheral blood, which have an intermediate morphology between hairy cells and prolymphocytes (negative TRAP staining and co- expression of CD19/CD103 without CD25
- Pretreatment with purine analogues or other chemotherapeutics
- Concomitant corticosteroid therapy
- Severe dysfunction of the heart (NYHA III or IV), the lung (WHO-Grade III or IV), the liver, except due to lymphoma (bilirubin \> 2 mg/dl, alkaline phosphatase, glutamate-oxalacetate transaminase and glutamate-pyruvate transaminase \> 2 x upper limit of normal), the kidneys (creatinin \> 2 mg/dl or creatinine clearance \< 50 ml/min), central nervous system diseases including psychoses.
- Proven HIV infection
- Active Hepatitis
- Other florid infections
- Anamnesis / diagnosis of other malignant disease (other than non-melanoma associated skin tumours or stage 0 in situ carcinoma of the cervix)
- Pregnant or lactating women
Interventions
DRUGCladribine s.c. injection, HCL treatment
Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
Locations(76)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02131753
Related Trials
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
NCT069651141 location
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
NCT0656136010 locations
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
NCT047757454 locations
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
NCT004125941 location
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
NCT048153561 location